| ²é¿´: 445 | »Ø¸´: 5 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
braynt24½ð³æ (СÓÐÃûÆø)
|
[½»Á÷]
ÇóÖú Ó¢ÎÄÕªÒª·Ò룡£¨10½ð±Ò·îÉÏ£©
|
||
|
±êÌ⣺A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel((R)) with CPG 7909, using two different formulations and dosing intervals. ÕªÒª£ºA Phase 1 study was conducted in 24 malaria naïve adults to assess the safety and immunogenicity of the recombinant protein vaccine Apical Membrane Antigen 1-Combination 1 (AMA1-C1)/Alhydrogel with CPG 7909 in two different formulations (phosphate buffer and saline), and given at two different dosing schedules, 0 and 1 month or 0 and 2 months. Both formulations were well tolerated and frequency of local reactions and solicited adverse events was similar among the groups. Peak antibody levels in the groups receiving CPG 7909 in saline were not significantly different than those receiving CPG 7909 in phosphate. Peak antibody levels in the groups vaccinated at a 0,2 month interval were 2.52 fold higher than those vaccinated at a 0,1 month interval (p=0.037, 95% CI 1.03, 4.28). In vitro growth inhibition followed the antibody level: median inhibition was 51% (0,1 month interval) versus 85% (0,2 month interval) in antibody from samples taken 2 weeks post second vaccination (p=0.056). |
» ²ÂÄãϲ»¶
µ÷¼Á
ÒѾÓÐ6È˻ظ´
Ò»Ö¾Ô¸ ½ÄÏ´óѧ 085602 »¯¹¤×¨Ë¶ 338·ÖÇóµ÷¼Á
ÒѾÓÐ12È˻ظ´
²ÄÁÏר˶(0856) 339·ÖÇóµ÷¼Á
ÒѾÓÐ8È˻ظ´
377Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
0703µ÷¼Á£¬Ò»Ö¾Ô¸Ìì½ò´óѧ319·Ö
ÒѾÓÐ6È˻ظ´
Ò»Ö¾Ô¸Äϲý´óѧ£¬085600£¬344·ÖÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
308Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
ÕÒµ÷¼Á
ÒѾÓÐ9È˻ظ´
Ò»Ö¾Ô¸Ö£ÖÝ´óѧ085600Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
316Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
monitor2885
ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)
¶Ó³¤
- ·ÒëEPI: 15
- Ó¦Öú: 6 (Ó×¶ùÔ°)
- ¹ó±ö: 0.339
- ½ð±Ò: 39490
- É¢½ð: 147
- ºì»¨: 22
- Ìû×Ó: 4996
- ÔÚÏß: 2174.3Сʱ
- ³æºÅ: 701577
- ×¢²á: 2009-02-15
- ÐÔ±ð: GG
- רҵ: Éú̬ϵͳÉú̬ѧ

2Â¥2009-07-02 23:11:21
braynt24
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 585.1
- Ìû×Ó: 58
- ÔÚÏß: 1.9Сʱ
- ³æºÅ: 439928
- ×¢²á: 2007-10-26
- ÐÔ±ð: GG
- רҵ: Ö²ÎïÒÅ´«Ñ§
3Â¥2009-07-02 23:34:31
ÓÄÑŰٺÏ
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 393.3
- Ìû×Ó: 131
- ÔÚÏß: 9.8Сʱ
- ³æºÅ: 730629
- ×¢²á: 2009-03-25
- ÐÔ±ð: MM
- רҵ: Äý¾Û̬ÎïÐÔ II £ºµç×ӽṹ
4Â¥2009-07-03 10:57:27
yanlili
½ð³æ (ÕýʽдÊÖ)
- ·ÒëEPI: 1
- Ó¦Öú: 2 (Ó×¶ùÔ°)
- ½ð±Ò: 96.5
- É¢½ð: 124
- Ìû×Ó: 453
- ÔÚÏß: 43.5Сʱ
- ³æºÅ: 671868
- ×¢²á: 2008-12-10
- ÐÔ±ð: MM
- רҵ: ÉúÎï´ó·Ö×ӽṹÓ빦ÄÜ
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
braynt24(½ð±Ò+10,VIP+0): 7-3 22:52
braynt24(½ð±Ò+10,VIP+0): 7-3 22:52
|
±êÌ⣺ͨ¹ý2ÖÖ²»Í¬µÄÅä·½ºÍÓÃÒ©¼ä¸ô£¬¶ÔѪҺ½×¶Îű¼²ÒßÃçºòѡҩÎïAMA1-C1/Alhydrogel((R)) with CPG 7909µÄ½×¶ÎÒ»µÄÑо¿ ÕªÒª£ºÔÚ24Ãû³ÉÄêÈËÉíÉϽøÐÐÁ˽׶ÎÒ»µÄÑо¿£¬ÒÔÆÀ¹ÀÖØ×éµ°°×ÒßÃç Apical Membrane Antigen 1-Combination 1 (AMA1-C1)/Alhydrogel with CPG 7909 ÔÚ2ÖÖ²»Í¬µÄÅä·½ºÍÓÃҩʱ¼ä°²ÅÅ£¨0ºÍ1¸öÔ£¬0ºÍ2¸öÔ£©Ïµİ²È«ÐÔºÍÃâÒßÔÐÔ¡£Á½ÖÖÅä·½¶¼ÓкܺõÄÄÍÊÜÐÔ£¬¶øÇÒ¾Ö²¿·´Ó¦µÄƵÂʺͲ»Á¼Ê¼þµÄ·¢ÉúÔÚС×éÖÐÀàËÆ ¡£½ÓÊÜÓÐCPG 7909 µÄÑÎÈÜÒºµÄС×éµÄ×î¸ß¿¹ÌåˮƽÓë½ÓÊÜÓÐCPG 7909 µÄÁ×ËáÑεÄС×éµÄ×î¸ß¿¹ÌåˮƽÏà±È£¬Ã»ÓÐÃ÷ÏԵIJî±ð¡£ÒÔ0£¬2¸öÔµļä¸ô×¢ÉäÒßÃçµÄС×éµÄ×î¸ß¿¹Ìåˮƽ±ÈÒÔ0£¬1¸öÔµļä¸ô×¢ÉäÒßÃçµÄС×éµÄ×î¸ß¿¹Ìåˮƽ¸ß2.5±¶(p=0.037, 95% CI 1.03, 4.28)¡£ÌåÍâÉú³¤ÒÖÖÆÓ뿹ÌåˮƽµÄ½á¹ûÒ»Ö£ºÖеÈÒÖÖÆÎª¿¹ÌåÖеÄ51%£¨0.1¸öÔ¼ä¸ô£©£¬¶Ô±È85%£¨0.1¸öÔ¼ä¸ô£©£¬¿¹ÌåÀ´×ÔÓÚµÚ¶þ´Î½ÓÖÖÒßÃç2¸öÐÇÆÚºóËùÈ¡ÑùÆ·¡£ ²»Ì«¶®Õâ¸ö£¬·µÃ²»ºÃ ½ö¹©²Î¿¼ ºÇºÇ |
5Â¥2009-07-03 11:42:54
braynt24
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 585.1
- Ìû×Ó: 58
- ÔÚÏß: 1.9Сʱ
- ³æºÅ: 439928
- ×¢²á: 2007-10-26
- ÐÔ±ð: GG
- רҵ: Ö²ÎïÒÅ´«Ñ§
6Â¥2009-07-03 22:52:38














»Ø¸´´ËÂ¥